Metrics to compare | CITI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCITIPeersSector | |
|---|---|---|---|---|
P/E Ratio | 18.7x | 15.4x | −0.3x | |
PEG Ratio | −1.65 | 0.64 | 0.00 | |
Price/Book | 1.4x | 2.9x | 2.6x | |
Price / LTM Sales | 1.0x | 1.4x | 3.0x | |
Upside (Analyst Target) | - | 29.1% | 62.0% | |
Fair Value Upside | Unlock | 24.4% | 8.2% | Unlock |
Citi Pharma Limited, together with its subsidiary, engages in the manufacturing and sale of pharmaceutical, medical chemical, botanical, APIs, formulations, and related healthcare products in Pakistan. The company offers active pharmaceutical ingredients (APIs), including analgesic/antipyretic, quinoline antibiotics, analgesic/NSAIDs, penicillins, sulfonamide antibiotics, cephalosporin antibiotics, anti-malarial, anti-diabetics, antioxidants, macrolide antibiotics, anti-asthmatic, modified APIs, anti-ulcer, corticosteroids, muscle relaxant, antidepressants/CNS agent, beta-lactam antibiotic, anti-histamine, anticonvulsant, antipsychotic, prokinetic, antifungal, antiprotozoal, anti-lipidemic/statin, antihypertensive, anti-dandruff, laxative, and diuretic. It also provides formulations; and nutraceuticals in tablet, capsule, syrup, sachet, and cream/ointment. In addition, the company is involved in the import, development, manufacturing, and marketing of veterinary drugs and related healthcare products. Citi Pharma Limited was incorporated in 2012 and is headquartered in Lahore, Pakistan.